Exploring the Therapeutic Potential of Crisaborole Gel in Atopic Dermatitis: A Review

Atopic Dermatitis (AD) is a long-lasting, inflammatory, and itchy skin disease related to asthma, hay fever, and a family history of the condition. It is the most common chronic skin disease in children, affecting 18% of 7-year-olds. The prevalence of AD in children in the United States is 17.2%, which is comparable to that in Europe and Japan. Greater socioeconomic groupings, fewer families, and metropolitan areas all have higher AD prevalence rates. It is thought that a mix of environmental and genetic factors produces the condition. The gene that codes for the skin matrix protein filaggrin is the most strongly linked genetic link currently identified with AD. Increased water loss due to AD-induced breakdown of the skin barrier leads to dry skin, heightening vulnerability to microbial colonization, allergy sensitization, and infection. PDE4, an intracellular enzyme present in inflammatory cells, is greater in persons with active AD and latent allergic rhinitis. Consequently, crisaborole, a PDE4 inhibitor, raises intracellular cAMP levels, activating Protein Kinase A (PKA), suggesting potential therapeutic options for the dysregulated inflammatory cycle associated with this disease. Thus, Crisaborole should be regarded as the safest and most effective option for treating atopic dermatitis. Crisaborole's specific mechanism, safety profile, and effectiveness in interrupting the inflammatory cycle make it an attractive treatment alternative, according to this study. Crisaborole is presented here as a potential remedy to address the research gap: the need for safer, more efficient therapies that target inflammatory pathways in AD.